NCT06361043Recruiting
Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
Summary
Despite multimodal therapy, patients with esophageal cancer have poor prognosis with 5-year overall survival around 25%. Considering tumor-related death as main reason for high mortality rate in those patients, treatment-related cardio-pulmonary toxicities could also play a role in this regard. Online adaptive radiotherapy offers the possibility for daily re-planning and therefore helps radiation oncologists to better spare the organs at risk and reduce radiation-induced toxicity. Tha aim of ARTEC is to assess the pulmonary toxicity in patients with esophageal cancer treated with online adaptive radiotherapy.
Inclusion criteria
• Written informed consent • Histologically confirmed diagnosis of AC (Adenocarcinoma) or SCC (squamos cell carcinoma) of the thoracic esophagus or gastroesophageal junction (Siewert I-II) • Patients with cT2-4b cN0 cM0 or cTany cN+ cM0 or any patient with early stage EC ineligible for upfront surgery • Age \>= 18 years old • Karnofsky Performance Status (KPS) \>= 70 or ECOG (Eastern Cooperative Oncology Group) 0 - 1 • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with patients before registration in the trial
Exclusion criteria
• Cervical esophageal cancers (15-18 cm from the incisors) • Definitive clinical or radiologic evidence of metastatic disease • Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment • Prior thoracic radiotherapy that would result in overlap of radiation therapy fields • Induction chemotherapy for the current malignancy prior to RCHT is allowed if last dose is no more than 90 days and no less than 10 days prior to registration • Pregnant and/or breast-feeding females
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- Insel Gruppe AG, University Hospital Bern(Other)
- Protocol no.
- 2023-01833
- Conditions
- Esophageal Cancer
- Interventions
- —
Locations · 1
- Bern, SwitzerlandInselspital, University of Berne, Deparftment of Radio-OncologyRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: April 25, 2024).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other identifiers
- 2023 · NIH grant
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.